JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.